Skip to content

Evaluation of Ajwain cream in patients with neuropathic foot

Evaluation of Ajwain cream in patients with neuropathic foot, a double blind randomized controlled clinical trial

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT201201248815N1
Enrollment
92
Registered
2012-06-12
Start date
2012-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuropathic pain.

Interventions

Intervention 1: A double-blind randomized placebo-controlled clinical trial Group of Ajwain cream: Cream is an oil in water semisolid formulation which is made up of almond oil (10%), Beeswax (5%),
Treatment - Drugs
Placebo
A double-blind randomized placebo-controlled clinical trial Group of Ajwain cream: Cream is an oil in water semisolid formulation which is made up of almond oil (10%), Beeswax (5%), Vaseline (10%)
double-blind randomized placebo-controlled clinical trial Group of placebo cream Placebo cream is an oil in water semisolid formulation which is made up of almond oil (20%), Beeswax (5%), Vasel

Sponsors

Vice Chancellor for Research, Shiraz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: The inclusion criteria for this study were encompassing nonpregnant adults with neuropathic pain diagnosis; diabetic neuropathy; postsurgical/posttraumatic neuropathic pain; moderate to severe pain persisted for 6 months or longer and presence of dynamic tactile allodynia or hyperalgesia in the site of pain in patients with normal cognitive and cooperation. In contrast, patients suffering from another type as severe as the above pain; a major depression or psychiatric disorder requiring special intervention; patients with history of hypersensitivity or allergic reactions to the essential oils or herbal medicament; children and pregnant volunteers and anybody who does not have the ability to participate were excluded.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Change or any declines in foot burn in neuropathic foot. Timepoint: The first day of addmision, middle of the trial (the day 15) and the end (the day 30). Method of measurement: visual analoge scale (from 0 to 10).

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad M. Zarshenas

Faculty of Pharmacy, Shiraz University of Medical Sciences

zarm@sums.ac.ir+98 71124242468

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026